DMAC vs TXN · $157.4M cap vs P/E 52, rev $17.68B
DiaMedica Therapeutics Inc (DMAC) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
DMAC does not have a complete income-statement cache yet.
Latest reported TXN revenue for 2025-12-31 was $17.68B. Net income was $5.00B. Revenue was up 13.0% from 2024-12-31 to 2025-12-31. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
DMAC currently screens at market cap $157.4M. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the DMAC and TXN stock pages for the full models.
Not investment advice.